What’s Next for Geographic Atrophy

1) Complement inhibitors: slowing lesion growth

The first FDA-approved treatments for GA arrived in 2023, and they target a key driver of inflammation in AMD: the complement system (a part of the immune
response). These medications are delivered as intravitreal injections (shots in the eyeyes, it sounds terrifying; yes, ophthalmologists do this all day).

• SYFOVRE (pegcetacoplan) targets complement component C3 and is dosed monthly or every other month, depending on the plan you and your
  retina specialist choose.
• IZERVAY (avacincaptad pegol) targets complement component C5 and is typically dosed monthly.

These drugs do not “cure” GA or bring dead retinal cells back to life. Their benefit is measured by how much they slow the growth of GA lesions
over time. Think of it like putting a speed limiter on a problem that otherwise tends to keep accelerating. That can matter a lot when the next tissue at
risk is the fovea (your sharpest central point of vision).

2) A realistic expectation: slowing progression can still be meaningful

It’s fair to ask: “If it doesn’t improve my vision, why bother?” Here’s the practical answer: small differences in lesion growth can translate into extra
time before certain daily tasks become impossibleespecially for people whose GA is threatening the center of the macula or whose other eye is doing most
of the heavy lifting.

For example, a person who still reads large print might be trying to preserve “reading vision” for as long as possible. Another person might prioritize
maintaining enough central vision for cooking safely or recognizing faces. The “right” choice depends on where the lesions are, how fast they’re growing,
and what you need your vision to do in your real life (not in a textbook).

3) Safety and tradeoffs: the part nobody should sugarcoat

Any intravitreal injection carries risks such as infection (endophthalmitis) and retinal detachment, though these are uncommon with proper technique.
Complement inhibitors also come with a known tradeoff: some patients develop wet AMD (neovascular AMD) and need additional treatment
(often anti-VEGF injections).

In addition, post-marketing safety reports have emphasized that retinal vasculitis and retinal vascular occlusion have been reported with
pegcetacoplan in real-world use. This is why retina specialists stress careful monitoring and prompt evaluation of new symptoms.

None of this is meant to scare youit’s meant to arm you with the kind of information that supports shared decision-making. GA treatment is a “risk,
benefit, values” conversation, not a vending machine purchase.

1) Treating earlierand choosing treatment more strategically

As clinicians gain more long-term experience, the discussion is shifting from “Should we treat GA?” to “When should we treat, and whom
does treatment help most?” Earlier intervention may matter more because there’s more functional retinal tissue left to protect.

Expect more personalized plans based on lesion location (especially how close it is to the fovea), growth rate, symptom burden, fellow-eye status, and
patient priorities. The future looks less like a universal protocol and more like a tailored roadmap.

2) Better imaging + AI to predict risk (and reduce guesswork)

GA has always been tracked with tools like optical coherence tomography (OCT) and fundus autofluorescence (FAF). What’s changing is how much more
informative these images are becomingespecially when paired with software that can quantify lesion area and detect subtle progression earlier.

In the near future, it’s likely you’ll see more clinics using automated measurements to answer questions like:
How fast is my GA expanding? Is it accelerating? Is my fovea threatened within the next year or two?

This matters because it improves timing: if you treat too late, you’re protecting tissue that’s already gone; if you treat too early, you might be adding
burden and risk before the benefit is meaningful. Smarter prediction tools help find the sweet spot.

3) Longer-acting options and easier delivery (fewer “shot appointments”)

Today’s regimen can be demanding. Monthly injections are time-consuming, stressful, and logistically hardespecially for older adults who rely on family or
transportation services. One obvious “what’s next” is making therapy more durable and the injection experience more streamlined (for example, improved
delivery systems and practice innovations).

Over time, expect competition to push toward longer intervals between treatments and more convenient administration. Even moving from monthly to every
other month can change a person’s life calendar (and their caregiver’s).

4) Combination therapy: tackling GA from more than one angle

Complement inhibition is the first chapter, not the whole book. GA is influenced by multiple processes: inflammation, oxidative stress, lipid metabolism,
mitochondrial dysfunction, and more. It’s reasonable to expect that future regimens may combine therapiessimilar to how other chronic diseases are treated.

A plausible future could look like: one drug to slow lesion growth, another to protect stressed photoreceptors, and a third to optimize retinal metabolism.
Not everyone will need all of that, but the direction is toward layered strategies rather than a single magic bullet.

5) Gene therapy: “one-time” approaches that could reduce long-term burden

One of the most watched frontiers is gene therapy aimed at dialing down the complement cascade or strengthening protective pathways inside the retina. The
appeal is obvious: instead of frequent injections, a one-time treatment could potentially provide longer-lasting control of disease drivers.

Several gene therapy programs are in development for GA. Some are designed to inhibit complement pathways, while others aim to alter gene expression linked
to inflammation, oxidative stress, or lipid handling in retinal cells. Early-stage data in this space is evolving, and it’s not yet “standard care,” but
it’s a major reason researchers and retina specialists are more optimistic than they were five years ago.

6) Regenerative and cell-based approaches (the “restore” conversation)

Slowing progression is importantbut what people want is restoration. That’s where cell-based therapies and regenerative medicine come in. The
idea is to replace or support damaged retinal pigment epithelium (RPE) and protect remaining photoreceptors.

These approaches are scientifically hard (the retina is not a forgiving place), but progress tends to happen in steps: better surgical delivery, better
cell survival, better integration, and better functional outcomes. Even partial restorationlike improved contrast sensitivity or reading abilitycould be a
major quality-of-life win.

7) Vision restoration tech: implants and “bionic” help for advanced disease

For people with severe central vision loss from GA, researchers are also studying implant-based systems designed to restore functional central vision using
electronic or photovoltaic stimulation. These are not mainstream clinical options yet, but clinical research has reported meaningful improvements in tasks
like reading letters and navigating using assisted vision systems.

If you’re thinking, “So, sci-fi is happening,” you’re not wrong. The more accurate version is: “engineering is finally catching up to biology,” and that’s
worth paying attention toespecially for advanced GA where traditional pharmacologic slowing may not be enough.

Work with a retina specialist on a plan (not just a diagnosis)

GA care works best when it’s proactive. That means regular monitoring, discussing treatment timing, and having a clear “if this, then that” plan for
symptoms that could signal wet AMD (like new distortion, sudden blurring, or a dark spot).

Protect your overall eye health

Lifestyle doesn’t replace medical care, but it matters. Evidence-based strategies commonly recommended in AMD care include not smoking, managing blood
pressure and cardiovascular risk factors, and discussing nutrition/supplements (such as AREDS2 formulations) with your eye care team when appropriate.

Use low vision tools early (they’re not “giving up”)

Low vision rehabilitation is one of the most underused superpowers in eye care. It can include magnifiers, optimized lighting, high-contrast settings,
text-to-speech tools, and training that helps you adapt efficiently. The earlier you use these supports, the easier the learning curve tends to be.

Translation: don’t wait until you’re furious at your mail. Get tools before the mail wins.

Will new treatments stop GA completely?

That’s the goal, but we’re not there yet. Current drugs slow lesion growth; future therapies may do moreespecially if combination approaches, longer-acting
strategies, and gene therapies continue to show benefit.

Will any treatment bring my vision back?

Current FDA-approved therapies are not designed to restore lost vision. The “restore” category is more likely to come from regenerative medicine, implants,
and advanced assistive technologies. Those are active areas of research, and early results in some device studies are encouraging, but availability and
eligibility will vary.

How do I know if treatment is worth it for me?

The most helpful conversation is specific: where your GA is, how fast it’s growing, whether your fovea is threatened, what your fellow eye is doing, and
what vision tasks matter most to you. Bring your real life into the exam roomyour work, hobbies, driving needs, reading habits, and caregiver support.